| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead |
| Ongoing | 4 | 110 | Europe | Symtuza, Tablet, Symtuza, Triumeq | Fundación SEIMC-GESIDA, JANSSEN CILAG S.A | HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04442737: A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain |
|
|
| Completed | 4 | 103 | US | D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen | Janssen Scientific Affairs, LLC | HIV-1 | 08/23 | 08/23 | | |
ReSTART, NCT04388904: Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. |
|
|
| Completed | 4 | 75 | US | Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC) | The Crofoot Research Center, Inc., Janssen Scientific Affairs, LLC | HIV-1-infection | 04/24 | 04/24 | | |
NCT05463783: Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain |
|
|
| Recruiting | 4 | 30 | US | Biktarvy, bictegravir/emtricitabine/tenofovir alafenamide, Symtuza, darunavir/cobicistat/emtricitabine/tenofovir alafenamide | East Carolina University, Janssen Scientific Affairs, LLC | HIV Infections, Obesity | 03/25 | 03/25 | | |
2018-003481-13: An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease -The Late Presenter Treatment Optimisation Study (LAPTOP)- |
|
|
| Not yet recruiting | 3 | 440 | Europe | Biktarvy, Symtuza, [J05AR], [J05AR22], Film-coated tablet, Biktarvy, Symtuza | NEAT ID Foundation, Gilead Sciences Inc, Janssen Pharmaceutica NV, Gilead Sciences, Inc., | Patients who present late on during their acquisition of the HIV-1 (Human Immunodeficiency Virus), A virus that damages patient's immune system causing the patient difficulty to fight off infections and diseases., Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 3 | 36 | Europe | Biktarvy, Symtuza | Chelsea and Westminster NHS Foundation Trust, Imperial College London, Gilead Sciences | Human Immunodeficiency Virus | 07/23 | 07/23 | | |
NCT03696160: The Late Presenter Treatment Optimisation Study |
|
|
| Active, not recruiting | 3 | 447 | Europe | Biktarvy, Symtuza | NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals | HIV/AIDS | 06/24 | 06/24 | | |